Erythema multiforme after the third dose of mRNA‐1273

Abstract

B27 negative uveitis under treatment with salazopyrin was admitted to the hospital due to the presence of high fever and mucocutaneous lesions. He had been vaccinated with the third dose against SARS-CoV-2 4 days before (mRNA-1273 -Moderna ® -while the first two doses had been mRNA-BNT162b2 -Pfizer-BioNTech ® -). On physical examination, he presented labial and palate mucositis, associating pain, swelling and meliceric crusts as well as erythematous-purpuric macular asymptomatic lesions located mainly on the periungual region of the fingers, palms, soles, and ears. Figure 1A-C. Slightly vesiculous (Some of them targetoid) millimetric erythematous lesions were also evident on the dorsal area. Figure 1D. Dermoscopy of the lesions revealed an erythematous-purpuric homogeneous pattern, without other relevant findings. Moreover, the patient presented both bilateral conjunctivitis and parotitis. Blood tests performed revealed a Reactive-C-Protein (RCP) of 119.1 mg/L as well as hyperferritinemia (553 ng/ml); cryoglobulins, and autoimmunity studies were anodyne. Chest X-ray examination was normal. A biopsy of one of the dorsal lesions was performed, revealing epidermal hyperplasia along with hyperkeratosis. Focal necrosis of the

Occurrence of erythema multiforme following COVID-19 vaccination: a review

“…Table 1 [ 8 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ] and Table 2 [ 39 40 41 42 43 44 ] presents the results obtained from evaluation of 31 eligible articles retrieved from the databases.…”